| Document |
Document Title |
|
WO/2001/060813A1 |
A beta-alanine derivative of the formula (I) wherein R?1¿ is hydrogen atom or an amino protective group; A is a lower alkylene group or a lower alkenylene group; R?2¿ is hydrogen atom or an amino group which may be substituted with an ...
|
|
WO/2001/059100A2 |
Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been iden...
|
|
WO/2001/058899A1 |
The invention relates to pyridine derivatives of formula (I), wherein the substituents and symbols are defined as indicated in the description, processes for the preparation thereof, their usage in the preparation of a pharmaceutical com...
|
|
WO/2001/059068A2 |
The invention relates to artificial bone chips (BFU = bone forming units), to cartilage transplants and bone transplants, to methods for the production thereof, and to their use in field of surgery. The artificial bone chips are comprise...
|
|
WO/2001/058853A1 |
Compunds of formula (1 and 1-1), wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, A, B have the meanings given within.
|
|
WO/2001/058906A1 |
The invention provides certain pyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. Formula (I) in which: A is a group of formula (a), (b) or (c).
|
|
WO/2001/058902A1 |
The invention provides certain heterocyclic compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy; in formula (I), A is a group of formula (a) or (b).
|
|
WO/2001/056576A1 |
The invention relates to a zaleplon-containing preparation that is characterized by being a transdermal therapeutic system in the form of an adhesive dressing. Said adhesive dressing comprises a backing layer, an adhesive, active substan...
|
|
WO/2001/057240A2 |
The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and a protein tyrosine phosphatase (PTP), e.g., PTPL1. The present invention provides methods for screening a PTP agonist or antagon...
|
|
WO/2001/052866A1 |
A composition for the treatment of adhesions that are formed as a result of an inflammatory response comprising an aqueous formulation containing the polysaccharide dextrin in an effective amount. The invention also discloses a method of...
|
|
WO/2001/053256A1 |
The invention relates to benzoylguanidines of formula (I), wherein R2 stands for -Y-p-(C¿6?H¿4?)-R11, -Y-m-(C¿6?-H¿4?)-R11 or -Y-o-(C¿6?H¿4?)-R11; R11 represents (C¿1?-C¿9?)-heteroaryl, which is bonded by C or N and is substitute...
|
|
WO/2001/053343A1 |
The present invention relates to novel human human polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods ...
|
|
WO/2001/051462A1 |
This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds having the structure (I) wherein A, B, R, R?1¿, p and q are as defined herein. The invention is also directed to pharmaceutical compositions conta...
|
|
WO/2001/049711A2 |
The invention relates to nucleic acid molecules encoding (poly)peptides having chemotaxis inhibiting polypeptides CHIPS activity, to recombinant vectors harboring such molecules, and the host cells carrying the vectors. The invention fur...
|
|
WO/2001/048149A1 |
Methods for isolating, purifying, culturing and differentiation-inducing bone marrow cells capable of differentiating into heart muscle cells; a method for proliferating bone marrow cells capable of differentiating into heart muscle cell...
|
|
WO2001003720A9 |
Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been iden...
|
|
WO/2001/045717A2 |
Pharmaceutical composition for the prophylactic treatment of secondary injury of tissue, said secondary injury being induced by primary injury of mainly surrounding tissue and being the result of a traumatic event, wherein the pharmaceut...
|
|
WO/2001/045716A1 |
Pharmaceutical composition for the prophylactic treatment of secondary injury of tissue, said secondary injury being induced by primary injury of mainly surrounding tissue and being the result of a traumatic event, wherein the pharmaceut...
|
|
WO/2001/046327A2 |
An adhesive composition that contains cyanoacrylate monomers and cyclic or alkyl- or phenyl-terminated linear polydimethylsiloxane is particularly useful in applications requiring flexibility and elasticity. A method of removing, reducin...
|
|
WO/2001/043745A1 |
The use of scopolamine salts for preventing the onset of epilepsy that might ensue after the condition of status epileticus, major head trauma, including those occasioned by neurosurgical trauma, and acute lesional events to the brain.
|
|
WO/2001/042241A1 |
There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
|
|
WO/2001/042288A2 |
The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host, cells, antibodies, agonists, and antagonists. The invention also ...
|
|
WO/2001/038316A2 |
The invention relates to compounds of the general formula (I), wherein R¿1? and R¿2? independently of one another represent H, -R¿6?, C¿3?-C¿8?-cycloalkyl, -(CH¿2?)¿n?-R¿7?, -(CH¿2?)¿n?-O-R¿6?, -(CH¿2?)¿n?-NH¿2?, -(CH¿2?)Â...
|
|
WO/2001/036462A2 |
Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will requi...
|
|
WO/2001/036604A2 |
Provided herein endotheliases and portions, particularly, the protease domains, and nucleic acids that encode the endotheliases. The endotheliases are transmembrane proteases expressed in endothelial cells. The nucleic acids and encoded ...
|
|
WO/2001/032216A2 |
The invention concerns a product comprising at least a NO synthase inhibiting substance associated with at least a phospholipase A2 inhibiting substance, separately or combined, for simultaneous therapeutic use, separately or spread over...
|
|
WO/2001/030759A2 |
NHE-1 inhibitor crystal of Formula (I), methods of using such NHE-1 inhibitor crystal and pharmaceutical compositions containing such NHE-1 inhibitor crystal. The NHE-1 inhibitor crystal is useful for the reduction of tissue damage resul...
|
|
WO/2001/030383A2 |
The invention relates to a medicament comprising 11-$g(b)-hydroxysteroid dehydrogenase inhibitors combined with an antigen in order to improve and optimize tolerance induction.
|
|
WO/2001/030328A2 |
The invention relates to the use of 2-amino-3,4-dihydro-quinazolines of formula (I) and to their pharmaceutically compatible salts for producing a medicament for treating and preventing ischaemic conditions. R1, R2 and R3 have the meanin...
|
|
WO/2001/030287A1 |
A non-invasive and non-systemic method for intradermal prevention or amelioration of pain from a surgically closed wound is disclosed. The method comprises topical delivery of a local anesthetic to an exterior to an exterior surface of a...
|
|
WO2001014557B1 |
The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interac...
|
|
WO/2001/024793A1 |
A therapeutic composition comprising an alkyl, aralkyl, alkoxyalkyl, or carboxyalkyl ester of 2-ketoalkanoic acid and a component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is disclosed. ...
|
|
WO/2001/025238A2 |
Disclosed are novel compounds of formula (I) wherein Ar¿1?, R¿a?, R¿4?, R¿5?, X and Y are defined below, which are useful as inhibitors of certain protein tyrosina kinases and are thus useful for treating diseases associated with suc...
|
|
WO/2001/022989A2 |
There are disclosed a method to enhance sternal treatment after sternotomy with or without removal of at least onE of thoracic arteries which comprises applying an agent for the treatment of sternum after sternotomy to or at around the s...
|
|
WO2000030668A9 |
The invention described herein relates to the discovery of methods and compositions for the inhibition of growth and/or migration of cells that have the P antigen, including but not limited to, cells of hematopoietic origin and endotheli...
|
|
WO/2001/021789A1 |
The invention relates to a catalytically active RNA molecule that is directed to mRNA molecules that encode the cell cycle relevant proteins cyclin E or E2F1. The catalytically active RNA molecule is a hammerhead ribozyme that induces th...
|
|
WO/2001/021628A1 |
The present invention relates to a compound according to Formula (I): A-(L-Y)¿p?, wherein A comprises at least one substantially cell-membrane impermeable pendant group; L comprises any suitable linker and/or spacer group; Y comprises a...
|
|
WO2000040612A9 |
IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
|
|
WO/2001/017531A1 |
A promotor of wound healing and an inhibitor of formation of a urethral stricture, particularly following surgical intervention or infection in the area. Specifically, the most preferred compound of the present invention, Halofuginone, c...
|
|
WO/2001/017568A2 |
In order to meet these needs, the present invention is directed to therapeutic and diagnostic agents capable of forming covalent bonds to blood and pulmonary fluid proteins or other components ex vivo or in vivo. The therapeutic agents o...
|
|
WO/2001/017614A2 |
Derivatives of antineoplastic agents are prepared. The derivatives are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
|
|
WO/2001/014886A2 |
Disclosed is a compound which inhibits binding between a target protein and a macromolecular ligand of the target protein. The compound comprises a targeting group, an attaching group and, optionally a linker group. In one aspect of the ...
|
|
WO/2001/012244A1 |
Use of fibrinogen multimers having at least 6 fibrinogen units as an ingredient for a fibrin sealant.
|
|
WO/2001/012775A2 |
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for p...
|
|
WO/2001/012622A1 |
The invention relates to the compounds of Formula (I), as well as the process for their production and their use as pharmaceutical agents.
|
|
WO/2001/012245A1 |
A composition for lubricating a joint is disclosed which comprises a solution or suspension of a phospholipid together with gelatin. The gelatin is preferably succinylated gelatin. The phospholipid, may be phosphatidic acid, phosphatidyl...
|
|
WO/2001/010323A1 |
This invention is using a heat exchange device (240) in combination with an anti-shivering mechanism that temporarily reduces shivering for lowering the body temperature of a patient. Various anti-shivering agents are disclosed including...
|
|
WO/2001/008685A1 |
The present invention relates to acyclic and cyclic amine derivatives for treating or preventing neuronal damage associated with neurological diseases. The invention also provides compositions comprising the compounds of the present inve...
|
|
WO/2001/009160A1 |
Methods are provided for generating nucleic acid ligands of CD40ligand. The methods of the invention use the SELEX method for the isolation of nucleic acid ligands. The invention also includes nucleic acid ligands to CD40ligand, and meth...
|
|
WO/2001/007436A2 |
This invention is directed to oxoazaheterocyclyl compounds which inhibit Factor Xa, to oxoazaheterocyclyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates ...
|
